Company Information

Company Takeda Pharmaceutical Company Limited
www.takeda.com
Type:
Company
Country:
Japan
Sector:
Pharmaceuticals & Biotechnology
Ownership:
Publicly Listed
Global Compact Status:
Active
Participant Since
31 March 2009
Letter of Commitment
Next Communication on Progress (COP) due on:
31 July 2025

Financial Information


Non-Financial Information

Affiliated Subsidiaries

Country Company Name
India Baxalta Bioscience India Pvt Limited
Switzerland Takeda Pharmaceuticals International AG

Communication On Progress

Published On Title Level/Status
23-Jul-2024 2024 Communication on Progress Submitted
16-Dec-2022 2022 Annual Integrated Report Active
20-Dec-2021 2021 Annual Integrated Report Learner
25-Dec-2020 2020 Sustainability Report Active
14-Jan-2020 Sustainable Value Report 2019 Active
31-Jul-2019 Grace Letter Not applicable
30-Oct-2018 Sustainable Value Report 2018 Advanced
30-Oct-2017 Sustainable Value Report 2017 Advanced
31-Oct-2016 Communication on Progress Advanced
02-Nov-2015 Communication on Progress Advanced
04-Nov-2014 Communication on Progress Advanced
10-Nov-2013 Communication on Progress Advanced
09-Nov-2012 Communication on Progress Advanced
08-Dec-2011 Annual Report 2011/ CSR Databook 2011 Advanced
08-Dec-2010 2010 Communication on Progress Not applicable
08-Dec-2009 2009 CSR Databook Not applicable

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.